Relapsed/Refractory Follicular Lymphoma

Oncology
5
Pipeline Programs
4
Companies
4
Clinical Trials
2 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
267%
Cell Therapy
133%
+ 1 programs with unclassified modality

On Market (2)

Approved therapies currently available

BeOne Medicines
BRUKINSAApproved
zanubrutinib
BeOne Medicines
Kinase Inhibitor [EPC]oral2025
U
TAZVERIKApproved
tazemetostat
Unknown Company
oral2020

Competitive Landscape

4 companies ranked by most advanced pipeline stage

BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
1
ZanubrutinibPhase 3Small Molecule1 trial
Active Trials
NCT05100862RecruitingEst. Jun 2030
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
Axicabtagene CiloleucelPhase 3Cell Therapy1 trial
Active Trials
NCT05371093Active Not Recruiting231Est. Oct 2030
Ipsen
IpsenChina - Tianjin
1 program
1
TazemetostatPhase 3Small Molecule1 trial
Active Trials
NCT04224493Recruiting612Est. Mar 2029
Regeneron
RegeneronTARRYTOWN, NY
1 program
Non-InterventionalN/A1 trial
Active Trials
NCT05338879Completed247Est. Oct 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Gilead SciencesAxicabtagene Ciloleucel
BeOne MedicinesZanubrutinib
IpsenTazemetostat
RegeneronNon-Interventional

Clinical Trials (4)

Total enrollment: 1,090 patients across 4 trials

NCT05371093Gilead SciencesAxicabtagene Ciloleucel

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Start: Sep 2022Est. completion: Oct 2030231 patients
Phase 3Active Not Recruiting
NCT05100862BeOne MedicinesZanubrutinib

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Start: Mar 2022Est. completion: Jun 2030
Phase 3Recruiting
NCT04224493IpsenTazemetostat

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Start: Jun 2020Est. completion: Mar 2029612 patients
Phase 3Recruiting
NCT05338879RegeneronNon-Interventional

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma

Start: Jun 2022Est. completion: Oct 2023247 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4m ago

Office Administrator

SystImmune
4m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
14m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
18m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
18m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,090 patients
Small Molecule is the dominant modality (67% of programs)
4 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)